- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03860662
The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex
Doctor, Physical Medicine and Rehabilitation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Spasticity is defined as increased resistance tied to speed against passive movements and is related to hyperactive reflexes after upper motor neuron lesions. The hemiplegia table, which develops after subsiding, brings many problems along with it. Spasticity is one of these problems. Spasticity frequently leads to difficulty in the activities of daily life. It delays functional recovery, causes pain, and leads to secondary complications.
The objective of spasticity treatment minimizes the negative effects of hypertension without endangering function. Systematic medication treatment (baclofen, diazepam, dantrolen, and tizanidine) or local treatment (botulinum toxin, phenyl injection) are administered in spasticity treatment. The botulinum toxin prevents the secretion of acetylcholine in nerve endings and creates a presynaptic neuromuscular block. There are numerous studies that show that botulinum toxin is effective in spasticity.
Baclofen is a gamma aminobutyric acid (GABA) agonist. It passes through the blood-brain barrier and binds to the GABAb receptors of the spinal cord. Baclofen decreases spasms, clonus, and resistance to germs.
Various studies of electrophysiological reflexes are conducted to evaluate spasticity and to study neuronal circuits. The electrophysiological test is a tool used in studying the changes in spinal cord function and spinal reflexes in patients. The flexor reflex known as the recoil reflex is a polysynaptic and multisegmental reflex. It provides for avoidance and protection from internal and external stimulants that may be harmful for the body.
The purpose of the study is to research the effect of oral baclofen treatment and botulinum toxin injection treatments over the electromyographic nociceptive flexor reflex (NFR) threshold in hemiplegic patients with spasticity.
PURPOSE OF THE RESEARCH The purpose of this thesis is to research the effect of oral baclofen treatment and botulinum toxin injection treatments over the electromyographic nociceptive flexor reflex (NFR) threshold in hemiplegic patients with spasticity. The results of the study evaluated the Modified Ashworth Scale, joint range of motion, muscle strength, Brunnstrom stages, Barthel daily life activities index, electromyographic nociceptive flexor reflex (NFR) threshold
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Hatay, Turkey
- Hatay Mustafa Kemal University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being between the ages of 18-60
- To accept voluntary participation in the study
- Spastic Hemiplegia (Modified Ashworth Scale 2 and above)
Exclusion Criteria:
- Pregnant women, breastfeeding and younger than 18 years
- To have medication and substance use causing neuropathy in the history of the disease and / or neuropathy
- Companies that have received botulinum toxin injection therapy and / or oral antispastic therapy within the last 6 months
- Have a history of allergies and hypersensitivity to usability drug
- Injection treatment planned purification hematoma, cleaning or skin lesion to be
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Spastic hemiplegia , Botox
Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release.
Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu).
Two antigenically distinct serotypes of BTX are available on the market as type A and B.
|
The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
botox
|
OTHER: Spastic hemiplegia, Baclofen
Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors.
The recommended dosing regimen is initiated with 5 mg 3 times a day.
It can be increased by 15-mg/d increments at 3-day intervals as needed.
Dosing should not exceed 80 mg/d.
|
The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
baclofen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
thershold of nociceptive flexor reflex
Time Frame: 6 weeks
|
The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
|
6 weeks
|
Barthel index
Time Frame: 6 weeks
|
The Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.
The index also indicates the need for assistance in care.The final score on the Barthel index ranges from 0, or complete dependence, to 100, or complete independence .
|
6 weeks
|
Vısual analog scale
Time Frame: 6 weeks
|
When using a VAS to assess pain, subjects are asked to indicate intensity by marking a (usually) 100-mm-long horizontal line that is labeled "no pain" at one end and "worst pain possible" at the other end.
This requires the patient to be able to equate the length of the line (as measured from the left-hand side to the point marked) with the amount of pain they are experiencing.
Higher values represent worse outcome.
|
6 weeks
|
Range of motion
Time Frame: 6 weeks
|
Range of motion (ROM) is the measurement of the amount of movement around a specific joint or body part
|
6 weeks
|
Modified Ashworth scale
Time Frame: 6 weeks
|
The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Higher values represent worse outcome. (0) No increase in muscle tone (1) Slight increase in muscle tone, manifested by a catch and release or byminimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension.(1+) Slight increase in muscle tone, manifested by a catch, followed by minimalresistance throughout the remainder (less than half) of the ROM.(2) More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved.(3) Considerable increase in muscle tone, passive movement difficult.(4) Affected part(s) rigid in flexion or extension |
6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Paralysis
- Hemiplegia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- GABA Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Baclofen
Other Study ID Numbers
- MustafaKUPMR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke Sequelae
-
Rennes University HospitalCompleted
-
Rennes University HospitalRecruiting
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Fondazione Don Carlo Gnocchi OnlusIstituto di Neuroscienze Consiglio Nazionale delle RicercheRecruitingStroke | Stroke SequelaeItaly
-
Dr. Noah Biotech Inc.CompletedStroke | Stroke SequelaeKorea, Republic of
-
University Hospital, BordeauxActive, not recruitingStroke | Stroke SequelaeFrance
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Transilvania University of BrasovSpitalul Clinic de Psihiatrie si Neurologie BrasovSuspendedStroke SequelaeRomania
-
Vetrea Terveys OyCompleted
Clinical Trials on Nociceptor flexor reflex
-
Steno Diabetes Center CopenhagenUniversity Hospital Bispebjerg and Frederiksberg; Hillerod Hospital, DenmarkCompletedDiabetic Foot Ulcer | Claw Toe | Hammer Toe | Mallet ToeDenmark
-
Tampere UniversityTampere University HospitalRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Recruiting
-
OAD OrthopaedicsUnknownAchilles TendinopathyUnited States
-
Cambridge University Hospitals NHS Foundation TrustCompletedChildhood CataractUnited Kingdom
-
Riphah International UniversityCompletedCarpal Tunnel SyndromePakistan
-
Istanbul Physical Medicine Rehabilitation Training...CompletedSpinal Cord InjuriesTurkey
-
Beijing Tiantan HospitalRecruitingMyocardial Injury | Trigeminal Cardiac ReflexChina
-
Istanbul Physical Medicine Rehabilitation Training...CompletedMuscle Hypertonia | Reflex, AbnormalTurkey
-
The Cleveland ClinicCompletedNephrolithiasis | Urolithiasis | Renal Stone